Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:09:33 EDT Thu 03 Jul 2025
Enter Symbol
or Name
USA
CA



Q:MDGL - MADRIGAL PHARMACEUTICALS INC - https://www.madrigalpharma.com.
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MDGL - Q1.3296.00·309.990.1300.15-0.010.0340.9103,5526,799299.52  311.21  295.4304377.46  200.6319:56:54Jun 2015 min RT 2¢

Recent Trades - Last 10 of 6799
Time ETExPriceChangeVolume
19:56:54Q305.004.842
19:54:21Q304.724.561
19:50:51Q306.005.848
17:37:34Q301.010.855
16:20:00Q300.15-0.0152
16:07:21Q308.948.781
16:04:10Q300.15-0.011
16:04:07Q300.15-0.011
16:04:03Q300.15-0.011
16:04:02Q300.15-0.011

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-20 06:31U:MDGLNews ReleaseMadrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra(TM)) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
2025-06-17 16:05U:MDGLNews ReleaseMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
2025-06-02 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference
2025-05-10 07:15U:MDGLNews ReleaseMadrigal Announces New Clinical Data Demonstrating Rezdiffra(TM) (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
2025-05-01 07:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates
2025-04-29 08:00U:MDGLNews ReleaseMadrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress
2025-04-18 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025
2025-04-16 07:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer
2025-03-11 08:00U:MDGLNews ReleaseMadrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors
2025-02-26 07:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra(TM) (resmetirom) in Patients with Compensated MASH Cirrhosis
2025-02-26 06:30U:MDGLNews ReleaseMadrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra(TM) (resmetirom) in Patients with Compensated MASH Cirrhosis
2025-02-21 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference
2025-02-12 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025
2025-01-13 06:45U:MDGLNews ReleaseMadrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra
2025-01-03 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
2024-11-06 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
2024-10-31 07:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates
2024-10-30 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals to Present Multiple Rezdiffra(TM) (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting(TM)
2024-10-21 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis
2024-10-18 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024